清空記錄
歷史記錄
取消
清空記錄
歷史記錄
芬蘭Aqsens Health公司及其中國合作伙伴歐際醫(yī)藥已獲得在中國江蘇省開展的一項前列腺癌和膀胱癌的臨床前研究項目的資助。
芬蘭圖爾庫。Aqsens Health很高興宣布與總部位于中國南京的歐際醫(yī)藥合作開展一個新的臨床前研究項目。該合作研究計劃于2024年在中國江蘇省進行前列腺癌和膀胱癌的臨床前試驗。這項研究將推進Aqsens Health的增強型時間分辨熒光(E-TRF)方法和生物傳感器的開發(fā),目的是提高從尿液中早期檢測前列腺癌和膀胱癌的能力。
南京的這項合作研究建立在Aqsens在芬蘭對前列腺癌和膀胱癌檢測的廣泛研究基礎上,還結合了Aqsens與芬蘭圖爾庫大學醫(yī)院合作的轉移性癌癥研究項目的領先實踐。該研究項目計劃將持續(xù)到2024年底。
合作的第一階段將側重于前列腺癌的臨床前試驗,目的是為申請臨床試驗許可開展基礎研究。前列腺癌試驗之后將進行膀胱癌研究。該試驗將與江蘇省腫瘤醫(yī)院和腫瘤專家合作進行,該項研究將為Aqsens獲得大規(guī)模臨床試驗許可提供支撐,并在未來中國市場上開展Aqsens Health在前列腺癌和膀胱癌診斷領域的注冊許可。
歐際醫(yī)藥的一個研究團隊將接受在Aqsens實驗室開發(fā)體系中使用E-TRF和生物傳感器的技術培訓,Aqsens實驗室的開發(fā)體系專門用于開發(fā)Aqsens Health的生物傳感器、運行E-TRF與生物傳感器分析以及培訓研究人員。培訓將分兩步進行,首先是在線培訓,然后在芬蘭圖爾庫的Aqsens Health實驗室進行實踐培訓。認證合格后,歐際醫(yī)藥的研究團隊將能夠在Aqsens Health科學團隊的支持下在中國進行復雜的研究工作。
歐際醫(yī)藥首席執(zhí)行官趙萬洲博士表示:“我們很高興能與Aqsens Health合作,采用Aqsens Health的E-TRF和生物傳感器技術,建立創(chuàng)新手段來篩查泌尿系統(tǒng)癌癥和潛在的其他疾病?!?/span>
趙博士還表示:“通過這種合作,我們將有效推進健康行動,從而在中國惡性腫瘤預防領域發(fā)揮一定的影響”。
Aqsens Health的首席執(zhí)行官Timo Teimonen表示:“無創(chuàng)采樣檢測具有許多優(yōu)勢,如發(fā)現(xiàn)新的生物標志物的可能性及效率大幅提高,研發(fā)成本大幅降低,中國對我們的E-TRF和生物傳感器表現(xiàn)出了濃厚的興趣,這些傳感器專門設計用于分析無創(chuàng)生物樣本。這是Aqsens Health邁出的重要一步,因為它使我們能夠接觸世界最大的單一市場?!?/span>
有關詳細信息,請聯(lián)系:
首席執(zhí)行官兼聯(lián)合創(chuàng)始人
Timo Tei monen
+358 40 5853105 | timo.tei monen@aqsens.com
關于:
Aqsens Health Oy是一家芬蘭醫(yī)療科技公司,開發(fā)針對高影響疾病的非侵入性篩查測試。該公司的研究項目側重于開發(fā)適合發(fā)展中經(jīng)濟體需求的基于唾液的傳染病檢測方法,并建立了準確且經(jīng)濟高效的泌尿系統(tǒng)腫瘤的篩查方法。這些測試使用了Aqusens Health的新型E-TRF方法和噬菌體生物傳感器相結合的技術系統(tǒng)。
歐際醫(yī)藥是一家專注于醫(yī)藥創(chuàng)新和生物科學技術的公司。歐際醫(yī)藥的研究由來自不同領域的優(yōu)秀國際科學家團隊領導,該公司在中國江蘇省獲得了多項創(chuàng)業(yè)榮譽。歐際醫(yī)藥總部位于中國南京,與中國的多家醫(yī)療機構有著廣泛深入的合作關系。
詳情鏈接:
https://www.aqsens.com/news-and-blog/aqsens-health-og-pharma-collaboration
Aqsens Health starting pre-clinical trialsfor urinary tract cancer detection in China
Aqsens Health and its Chinese partner OG Pharmaceuticals have received funding for ajoint prostate and bladder cancer pre-clinical and clinical research project in Jiangsu Province in China.
Turku, Finland. Aqsens Health is happy to announce a new preclinical and clinical research project with OG pharmaceuticals, based in Nanjing, China. The research partnership aims to perform prostate and bladder cancer pre-clinical trials in Jiangsu Province in 2024. The study will advance Aqsens Health’s E-TRF method and biosensor development with a goal to improve the early detection of prostate and bladder cancers from urine.
This research collaboration in Nanjing builds upon Aqsens' extensive research on prostate and bladder cancer detection in Finland and it also incorporates leading practices derived from Aqsens’ research project on metastatic cancer in partnership with Turku University Hospital. The project is planned to last until the end of 2024.
The ? rst phase of the collaboration will focus on pre-clinical trials for prostate cancer with the aim to apply for permission to perform clinical trials. The prostate cancer trial will be followed by a bladder cancer study. The trials will be conducted in collaboration with Jiangsu Cancer Hospital and expert oncologists, and will enable Aqsens to obtain the permission for a large-scale clinical trial and the certi?cation of Aqsens Health’s AQ Prostate and AQ Bladder in the Chinese market.
A research team from OG Pharmaceuticals will be trained to use E-TRF and biosensor with the AQ Lab development environment, which was purposely built to be used in developing Aqsens Health’s biosensors, running E-TRF and biosensor analyses, and training research personnel. The training will be conducted in two steps, ? rst online and then physically at Aqsens Health’s laboratories in Turku. After certi?cation the researchers will be able to conduct complex research work in China under the supervision of Aqsens Health’s scienti?c team.
OG Pharma quote
“We are excited to collaborate with Aqsens Health to build innovative means to screen urinary tract cancers and potentially other diseases as well using their E-TRF and biosensor technology,” says OG Pharmaceuticals CEO, Dr. Wanzhou Zhao.
“With this collaboration we can be a part of something that can have an impact on preventive health actions in China,” Dr. Zhao continues.
“ Non-invasive sampling has many advantages, like the possibility of discovering new complementary biomarkers and superior cost ef?ciency, and China has shown strong interest towards our E-TRF and biosensors which are speci?cally designed to analyze non-invasive, biological samples. This is an important step for Aqsens Health as it gives us access to the world's largest single market,“ concludes Aqsens Health’s CEO Timo Tei monen.
For more information, contact:
CEO and Co-Founder
Timo Tei monen
+358 40 5853105 | timo.tei monen@aqsens.com
About:
Aqsens Health Oy is a Finnish med tech startup developing non-invasive screening tests for high-impact diseases. The company’s research projects focus on developing saliva-based infectious disease detection ?t for the needs of developing economies, and establishing an accurate and cost-ef?cient urine-based screening test for urinary tract cancers. The tests use Aqsens Health’s novel E-TRF method in combination with phage-biosensors.
Nanjing OG Pharmaceuticals Ltd. is a company focused on pharmaceutical innovations and bioscience technologies. OG P harma’s research is led by an accomplished international team of scientists from various ?e lds, and the company has been awarded several entrepreneurial honors in Jiangsu Province. OG P harma is based in Nanjing, just north of Shanghai, and works in broad connection with hospitals in China.
南京歐際醫(yī)藥科技服務有限公司是一家專業(yè)提供創(chuàng)新藥物研發(fā)關鍵技術解決方案的高科技服務外包公司,為國家衛(wèi)生計生委醫(yī)藥衛(wèi)生科技發(fā)展發(fā)展研究中心“重大疾病防治科技行動計劃”GLP聯(lián)盟成員單位,為江蘇省藥物研究與開發(fā)協(xié)會科技服務站,為南京市海外聯(lián)誼會經(jīng)濟科技委員會主任委員單位、南京市鼓樓區(qū)“醫(yī)藥創(chuàng)新技術轉移服務平臺”。秉承創(chuàng)新、合作、服務的企業(yè)文化,公司為國內外客戶提供從轉化醫(yī)學研究、創(chuàng)新藥物設計、優(yōu)化、合成、制劑、藥物篩選、成藥性評價、新藥臨床前研究的全流程研發(fā)服務,技術平臺涉及醫(yī)學、細胞生物學、分子生物學、生物化學、免疫學、藥物化學、藥理學、藥劑學、生物信息學等多個領域。企業(yè)信用評價AAA級信用企業(yè)。創(chuàng)新改變未來,科技服務健康!
實驗室地址:南京市棲霞區(qū)緯地路9號江蘇生命科技創(chuàng)新園F6棟101,103,105,107,115,528,530